# Adalimumab PK Bioequivalence Study to EU and US Sourced Humira

> **NCT02472912** · PHASE1 · COMPLETED · sponsor: **Mylan Inc.** · enrollment: 270 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **BIOLOGICAL:** BMO-2
- **BIOLOGICAL:** EU-Humira
- **BIOLOGICAL:** US-Humira

## Key facts

- **NCT ID:** NCT02472912
- **Lead sponsor:** Mylan Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2015-05
- **Final completion:** 2015-06
- **Target enrollment:** 270 (ACTUAL)
- **Last updated:** 2022-03-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02472912

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02472912, "Adalimumab PK Bioequivalence Study to EU and US Sourced Humira". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02472912. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*